Clinical trial · Interventional
Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
PROSPECTIVE CONTROLLED STUDY FOR THE OPTIMIZATION OF THERAPY IN CHRONIC MYELOID LEUKEMIA (CML): MULTICENTRIC STUDY FOR THE EVALUATION OF INTERFERON ALPHA VS ALLOGENIC BM TRANSPLANTATION WITH CHEMOTHERAPY IN CML
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of various combination chemotherapy regimens or bone marrow transplantation in treating patients with chronic myelogenous leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (9)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| allogeneic bone marrow transplantation | Procedure | — | UNRESOLVED |
| autologous bone marrow transplantation | Procedure | — | UNRESOLVED |
| busulfan | Drug | Busulfan | ALIAS |
| cytarabine | Drug | Cytarabine | ALIAS |
| hydroxyurea | Drug | Hydroxyurea | ALIAS |
| idarubicin | Drug | Idarubicin | ALIAS |
| peripheral blood stem cell transplantation | Procedure | — | UNRESOLVED |
| radiation therapy | Radiation | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Newly diagnosed chronic myelogenous leukemia in chronic phase
* Philadelphia chromosome- or bcr/abl-positive
* Cytogenetic negativity (analyzed separately) allowed if at least 1 of the following criteria is met:
* Malaise with decreased performance status
* Weight loss of more than 10% within the past 6 months
* Fever more than 38.5 C for 5 consecutive days
* Symptomatic splenomegaly
* Leukocyte count greater than 50,000/mm\^3
* Platelet count greater than 1,000,000/mm\^3
PATIENT CHARACTERISTICS:
Age:
* Any age
Performance status:
* See Disease Characteristics
Life expectancy:
* Not specified
Hematopoietic:
* See Disease Characteristics
Hepatic:
* Not specified
Renal:
* Not specified
Other:
* No other medical condition that would reduce life expectancy
* No other uncontrolled malignancy
* Not pregnant
* No other contraindication to study therapy
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* No prior interferon
Chemotherapy:
* No prior cytotoxic therapy
Endocrine therapy:
* Not specified
Radiotherapy:
* No prior radiotherapy
Surgery:
* Not specifiedReferences
Publications (0)
Data not yet available